Author:
Wilder-Smith A.,Longini I.,Zuber P. L.,Bärnighausen T.,Edmunds W. J.,Dean N.,Spicher V. Masserey,Benissa M. R.,Gessner B. D.
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Council for International Organizations of Medical Sciences. CIOMS Guide to Active Vaccine Safety Surveillance: Report of CIOMS Working Group on Vaccine Safety. Geneva: CIOMS; 2017.
2. Andrews N. Epidemiological designs for vaccine safety assessment: methods and pitfalls. Biologicals. 2012;40(5):389–92.
3. Saadatian-Elahi M, Horstick O, Breiman RF, Gessner BD, Gubler DJ, Louis J, Parashar UD, Tapia R, Picot V, Zinsou JA, et al. Beyond efficacy: the full public health impact of vaccines. Vaccine. 2016;34(9):1139–47.
4. Clemens J, Brenner R, Rao M, Tafari N, Lowe C. Evaluating new vaccines for developing countries. Efficacy or effectiveness? JAMA. 1996;275(5):390–7.
5. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386(9996):857–66.